~," Multidrug resistance for many types of cancer outside the central nervous system (CNS) has been found to be due to the overexpression of the multidrug resistance gene MDRI, of which the gene-product Pglycoprotein acts as a membrane-bound efflux pump for many anticancer drugs. To examine whether brain tumors overexpress the MDRI gene, 25 brain-tumor specimens were subjected to Northern blot analysis: 10 gliomas, eight meningiomas, three schwannomas, one malignant lymphoma, and three tumors metastatic to the brain. Ten fresh-frozen autopsy specimens of various parts of normal brain were also analyzed. Blots were hybridized with ~2P-labeled Chinese hamster eomplementau deoxyribonucleic acid (cDNA) and ~2P-labeled human MDRI cDNA. The MDR1 gene messenger ribonucleic acid (mRNA) was detected in two tumors using the Chinese hamster probe (one sphenoid wing meningioma and one metastatic prostate tumor) and in one CNS lymphoma using the human probe. Intact mRNA could not be extracted from the fresh-frozen autopsy specimens of normal brain. Seventeen tumors were examined for P-glyeoprotein by immunohistochemical staining using murine monoclonal antibody C219: eight gliomas, eight meningiomas, and one craniopharyngioma. The neoplastic cells from two gliomas and three meningiomas and the blood vessels within six gliomas and two meningiomas stained positively for P-glycoprotein. Seven of 10 normal brain specimens stained positively for P-glycoprotein in blood vessels but no specimen demonstrated staining of parenchymal cells. This study demonstrates that the MDRI gene can be detected in normal brain, and in malignant, benign, and metastatic lesions. P-glycoprotein can be present in tumor blood vessels even when it is not seen in neoplastic cells. Although the role of P-glycoprotein in tumor blood vessels needs to be further examined and more clearly defined, drug resistance in malignant primary' brain tumors may result from characteristics not solely of neoplastic cells but also tumor vasculature.
R
ESlSTANCE to chemotherapy remains a major obstacle in the treatment of patients with primary brain tumors. Recently, various human carcinomas, including liver, kidney, adrenal, and colon tumors, have been shown to be simultaneously resistant to multiple different hydrophobic drugs of natural product origin including Adriamycin (doxorubicin), vincrisline, colchicine, and etoposideY 9 m. t_,..9.21.22 Multidrug resistance for this broad category of agents was found to be associated with decreased intracellular drug accumulation and increased expression of a highly conserved gene that has been given the name "multidrug resistance (MDR) gene." The MDR gene family in humans has two members, MDRI and MDR2. 4 The MDRI gene is transcribed into a 4.5-kilobase (kb) messenger ribonucleic acid (RNA) and the gene product is a membrane-bound glycoprotein of 170,000 D called "P-glycoprotein" which acts as an energy-dependent efflux pump for the anticancer drugs mentioned above. The function of the MDR2 gene is unknown. <2S Multidrug resistance of cancers that exhibit overexpression of the MDRI gene can be overcome when competitive inhibitors such as calcium channel blockers and calmodulin inhibitors block P-glycoprotein-mediated drug effiux. Clinical trials based on the rationale that P-glycoprotein inhibitors should be given along with chemotherapeutic agents have been initiated.tl If malignant brain tumors overexpress the MDRI gene, new possibilities could be opened for the treatment of these lesions, which currently result in a dismal patient outcome.
Using Northern blot analysis, we examined whether malignant, benign, and metastatic lesions to the brain overexpressed MDR 1. Normal brain sections were also analyzed. To complement these studies, immunohistochemical staining was utilized using a murine monoclonal antibody with high specificity for P-glycoprotein.
Materials and Methods

Specimens for RNA Analysis
All specimens were obtained in accordance with the Johns Hopkins Joint Committee for Clinical Investigation guidelines. Fifty-seven sequential tumor biopsy specimens were obtained in the operating room, quickfrozen in liquid nitrogen, and stored at -70~ After total RNA extraction and oligo-dT chromatography, 8 25 of these 57 specimens yielded a sufficient amount of messenger RNA (mRNA) for analysis. The 25 specimens included four recurrent glioblastomas multiforme, three glioblastomas multiforme, one anaplastic astrocytoma, two low-grade astrocytomas, eight meningiomas, three schwannomas, one malignant lymphoma, and three metastatic tumors. Eight of these specimens were also analyzed by immunohistochemical staining for P-glycoprotein. Ten fresh-frozen autopsy specimens provided by the Johns Hopkins Hospital Brain Bank were also subjected to Northern blot analysis. These 10 biopsy specimens included two each from the cortex, white matter, amygdala, cerebellum, and hippocampus. The Chinese hamster ovary drug-resistant cell line CHRC5 (high MDR1 expressor) was used for the positive control, and the Chinese hamster ovary wild type cell line AuxB1 was used for the negative control (low MDR1 expressor).
RNA Preparation
Samples were homogenized in guanidine isothiocyanate and RNA was extracted by cesium chloride gradient centrifugation. 8 Total RNA concentrations were determined spectrophotometrically. Poly(A)+ RNA was isolated by oligo-dT chromatography. 8
Northern Blot Analysis
Messenger RNA samples were size-fractionated on 0.8% formaldehyde-agarose gels and transferred onto nitrocellulose.17 Blots were baked for 2 hours at 80~ and prehybridized for 4 hours at 42~ in 50% formamide, 5 x Denhardt's medium, 0.05 M NaH2PO4 (pH 7.4), and 0.015 mg/ml denatured herring sperm, using a method modified from that of Maniatis, et 0.08 29 metastatic adenocarcinoma 0 * Ratio in optical density units of MDR l mRNA:B-actin for AuxB 1 (low MDRI expressor), CHRC5 (high MDRI expressor), and human brain-tumor specimens using the Chinese hamster eDNA probe. CNS = central nervous system. Intact mRNA could not be extracted from normal brain fresh-frozen autopsy specimens.
? Positive MDRI mRNA expressor. :~ Detected using human MDRI eDNA probe (with the human MDRI eDNA probe. CHRC5 MDRI mRNA:B-actin = 0.58).
Hybridization with 3'-P-labeled human /3-actin cDNA verified intact mRNA samples and standardized quantities of mRNA. ~3 After hybridization, filters were washed twice for 20 minutes each at 42~ in 50% formamide, 5 x SET (0.75 M NaC1, 5 mM ethylenediaminetetra-acetic acid, 50 mM Tris, pH 7.8), and 0.25% sodium dodecyl sulfate (SDS), with a final wash at 65~ in 0.5 x SET and 0.5% SDS (modified from the method of Maniatis, et al. ~s).
Autoradiography and Data Analysis
Autoradiographs were exposed at -70"C on Kodak XAR film with special screens.{ Densitometry imaging was performed on an LAI Automated Biological Medical Image Analysis System.w The MDR1 mRNA:~-.~ Cronex Lightning-Plus screens manufactured by Du Pont Co., Wilmington, Delaware.
w LAI automated Biological Medical Image Analysis System manufactured by Loats Associates, Inc., Westminster, Maryland.
M u l t i d r u g resistance gene expression in brain t u m o r s
Fl(;. 1. Representative Norlhcrn blot findings of positive control and tumor specimens hybridized with human MDRI complement deoxyribonucleic acid (eDNA) probe (A), Chinese hamster eDNA probe (B), and /~-actin probe (C). Positive control CHRC5 is labeled C5: patient specimens are as follows: 8, 11 = recurrent glioblastoma multiforme: 12 = glioblastoma mulfiforme: 6 = Low-grade astrocytoma: t4 = oligodendroglioma; 16 = meningioma: 13 = schwannoma" 9 = malignant lymphoma" and 7, 10. and 15 = metastatic tumors. Positive expressors arc noted b5 arro~ in Specimens 7, 9, and 16 using the human probe and Specimens 7 and 16 using the Chinese hamster probe.
actin signal ratio was calculated for each specimen. Expression of MDR1 was defined as positive in cases with a discrete band at 4.5 kb and an MDR1 mRNA:/~-actin signal ratio above that of the low MDRI expressor, AuxB1. Samples exhibiting smears of degraded RNA and no band at 4.5 kb were eliminated from further analysis.
Irnrnunohistochemical Study
Seventeen brain-tumor biopsy specimens, eight of which were examined by Northern blot, were analyzed using immunohistochemistry. Specimens included three recurrent glioblastomas multiforme, three glioblastomas multiforme, one anaplastic astrocytoma, one oligodendroglioma, eight meningiomas, and one craniopharyngioma. Eleven flesh-frozen autopsy specimens were also examined using immunohistochemistry, including four hippocampus, two cerebellum, two amygdala, and three cortex biopsy specimens. To provide positive and negative controls, cultures of Chinese hamster ovary cell lines CHRC5 and AuxB1, respectively, were harvested by scraping, then were pelleted, frozen, and sectioned. Tissue sections 10 u thick were made using a cryostat, then air-dried and immediately incubated with the primary murine monoclonal antibody C219L1 at a concentration of 5 ug/ml. Monoclonal antibody C219 recognizes an epitope of P-glycoprotein on the inner surface of the cell membrane. Therefore, C219 incubation medium contained 0.1% Triton x 100. Positive (CHRC5) and negative (AuxB 1) controls were run concurrently. Normal horse serum, 1%, served II Primary murine monoclonal antibody C219 manufactured by Centocor, Malvern, Pennsylvania. as nonreactive control.:" Slides were kept overnight in a moisture chamber at 4~ Secondary, antibodies were biotinylated horse anti-mouse immunoglobulin G (heavy + light-chain specific) affinity-purified antibodies followed by avidin-biotin-peroxidase complexes. '4 Following a wash in phosphate-buffered saline, pH 7.4, and 0.05 M Tris buffer, pH 7.7, the sections were incubated with 0.5% filtered 3,3-diaminobenzidine in 0.01% H20:. ~ After a wash and counterstaining with hematoxylin, slides were mounted with Permount. 7 All slides were examined by three independent observers. Staining for P-glycoprotein was designated as strongly positive (++), weakly positive (+), or absent (-).
Results
Northern Blot Analysis
The ;~-actin probe signal verified intact mRNA for 25 brain-tumor specimens. The MDR1 mRNA:/3-actin signal ratio for each specimen is presented in Table 1 . Expression of MDRI mRNA was detected in three tumors. The Chinese hamster probe detected MDRI mRNA expression in one sphenoid wing meningioma (Specimen 16) in a patient with an aggressive tumor that required repeated resections, and one metastatic prostate tumor (Specimen 7) in a patient with known progate cancer and no prior chemotherapy. The Northern blot results for these cases can be seen in Fig. 1 . In one additional case, a patient with a central nervous system lymphoma and a prior history, of Hodgkin's disease, MDRI mRNA expression was detected using the human probe (Specimen 9). This patient had received prior chemotherapy consisting of six cycles of the MOPP protocol (nitrogen mustard, vincristine, procarbazine, and prednisone) 2 years prior to her crani- otomy. Based on the criteria for MDR 1 mRNA expression stated above, Specimens 2, 6, 8, and 13 had MDR 1 mRNA:B-actin ratios greater than 0.08 but no discrete bands at 4.5 kb, and were therefore not considered MDR1 mRNA expressors. Specimens 6 and 8 were also noted to have low ~-actin signals, which may have influenced detection of MDR1 mRNA expression, as did Specimens 11,41, and 46. The Northern blot results together with clinical correlations are summarized in Table 2 . Using the /3-actin probe, we found that we were unable to obtain intact mRNA from any of the normal fresh-frozen autopsy specimens. This was not unexpected, considering the nature of the source of the specimens.
Imrnunohistochernical Findings
A summary of immunohistochemical results with clinical correlation is provided in Table 2 . Two patterns of P-glycoprotein staining were observed: staining of penetrating tumor vessel endothelia ( Fig. 2A and B) and/or staining of neoplastic cells (Fig. 2C and D) . Staining of neoplastic cells occurred uniformly throughout the entire specimen or in isolated regions: one recurrent glioma and two meningiomas stained uniformly for P-glycoprotein, and one anaplastic oligodendroglioma and one meningioma stained in isolated regions. Neoplastic cells in two of eight gliomas and three of six meningiomas demonstrated P-glycoprotein: neoplastic cells in one glioblastoma multiforme and one meningioma stained very positively for P-glycoprorein, and neoplastic cells in one anaplastic astrocytoma and two meningiomas stained weakly positively for Pglycoprotein. Tumor vasculature stained positively in six of eight gliomas (seven of which were high-grade gliomas) and in four of six meningiomas. Penetrating blood vessels in four glioblastomas multiforme, one anaplastic astrocytoma, and one meningioma stained very positively for P-glycoprotein, and blood vessels in one glioblastoma multiforme and three meningiomas stained weakly positively for P-glycoprotein. Four of eight gliomas stained positively for P-glycoprotein within the tumor vasculature, with no staining of neoplastic cells ( Fig. 2A and B) , in contrast to one of six meningiomas. Two of eight gliomas demonstrated Pglycoprotein in both the tumor vasculature and neoplastic cells, as opposed to three of four meningiomas. In no case was staining present in neoplastic cells and not in the blood vessels. Due to nonspecific staining in the control specimens, two meningiomas were excluded from further analysis.
Immunohistochemical results of normal brain freshfrozen autopsy specimens is presented in Table 3 . Normal brain specimens demonstrated weakly and strongly positive staining of the vasculature only, with no staining in parenchymal ceils. Six regions demonstrated strongly positive staining of the penetrating vasculature: one specimen from the hippocampus, two from the cerebellum, one from the amygdala, and two from the cortex. One region of the hippocampus showed weakly positive staining for penetrating vessels. One specimen from the hippocampus, one from the cerebellum, and one from the amygdala stained negatively for both vessels and cells. The remaining hippocampal specimen was excluded from analysis due to nonspecific staining secondary to autolytic changes.
Discussion
By Northern blot analysis, three of 25 brain-tumor specimens demonstrated detectable MDR1 mRNA expression. The human probe identified one case not * GBM = glioblastoma multiforme; ca = carcinoma; oligo = oligodendroglioma, met adeno = metastatic adenocarcinoma: ND = not done; NA = data not available; craniopharyn = craniopharyngioma.
3" Immunohistochemieal staining pattern: ++ = strongly positive; + = weakly positive; -= absent: NSS = excluded for nonspeeific stain in specimen controls.
:~ Where relevant, the interval between chemotherapy and craniotomy is given in parentheses. BCNU = 1,3-bis(2-chloroethyl)-l-nitrosourea; MOPP = nitrogen mustard, vincristine, procarbazine, and prednisolone. sensitive technique to detect MDR 1 expression in brain due to the often isolated distribution of P-glycoprotein. Messenger RNA constitutes merely 5% of the total RNA prepared from heterogeneous tissue samples, whereas only a small percentage of tissue such as the penetrating tumor capillaries or an isolated pocket of tumor cells may express MDRI. Therefore, it is not surprising that some positive specimens are not detected by Northern blot analysis. It is also not surprising that autopsy specimens, collected at various times postmortem, do not represent sources of intact mRNA of the same quality as operating room specimens, fresh-frozen at the time of surgical excision.
The MDR gene is highly conserved and retained throughout the evolution spectrum from bacteria through mammals. 3 The MDR1 gene product, P-glycoprotein, has been found to act as an efflux pump and play an integral role in the removal of wastes and toxic substances from the cell. ~ Expression of MDR1 in normal tissue has been demonstrated in liver, kidney, and colon. ~' 23 Consistent with the results of this study, P-glycoprotein has been found by other investigators in normal brain within the endothelial cells of capillaries in the cortex, hippocampus, and cerebellum. TM The role of P-glycoprotein has been hypothetically related to the blood-brain barrier mechanism2 "24 Its presence within tumor vasculature may also be related to the removal of toxic substances. P-glycoprotein within the vessels of primary malignant brain tumors could pump chemotherapeutic agents back into the vasculature system before the drugs reach the neoplastic cells. On the other hand, P-glycoprotein may play a role in the enhanced removal of these agents from the interstitial space of neoplastic tissue.
In the majority of cases of high-grade gliomas, Pglycoprotein was present in tumor vessels even when it was not present in neoplastic cells. Although the exact part that this glycoprotein plays in tumor and/or normal vasculature needs to be further examined and more clearly defined, drug resistance in primary malignant brain tumors may result from the characteristics not solely of neoplastic cells but also of the tumor vasculature. Tumors in these situations would manifest drug resistance in vivo and may be drug-sensitive in vitro. This might partially explain why the results of in viltT~ chemotherapy testing have not correlated well with patient outcomeJ ~ In our series, one-half of the cases that demonstrated P-glycoprotein exclusively in tumor vessels had previously received chemotherapy, which suggests that chemotherapeutic agents may induce Pglycoprotein in tumor vasculature without inducing it in neoplastic cells.
Expression of the MDRI gene and P-glycoprotein was detected in primary malignant, benign, and tumors metastatic to the brain. P-glycoprotein was evident in neoplastic cells but was more widely apparent in penetrating tumor vasculature of the glioma specimens, where it may play a unique role in drug resistance. With widespread use of natural-product hydrophobic drugs in pediatric and adult brain-tumor chemotherapy protocols, ~5~ the presence of MDRI gene expression in malignant primary, brain tumors must be further examined, and its overall importance more clearly defined.
